Big effect
Intravenous vitamin C nearly doubled median survival in a meta-analysis of cancer patients — but the effect came from clinical studies without blinding, and progression-free survival didn't budge.
This is one of the first pooled analyses on IV vitamin C and cancer survival, so the finding is provocative but far from settled—especially since the same review found no improvement in progression-free survival, meaning the clock on living longer ticked slower while the cancer itself didn't show a similar pause.
A meta-analysis of 8 studies found that cancer patients given high-dose intravenous vitamin C lived nearly twice as long on average compared to those who didn't receive it. However, the studies weren't blinded, and the same analysis found zero benefit for how long the cancer stayed under control, which tempers the headline result.
Where this fits in the evidence
This is among the first studies we've indexed on Vitamin C for Improved Overall Survival — treat it as an early signal until more research accumulates.
The study
- Meta-Analysis
- 2025-07-01
- International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition
- PubMed: 40613397
- DOI: 10.31083/ijvnr37372
- Full study breakdown →
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.